BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 7923138)

  • 21. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice.
    Singhal A; Fohn M; Hakomori S
    Cancer Res; 1991 Mar; 51(5):1406-11. PubMed ID: 1997178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
    Karanikas V; Thynne G; Mitchell P; Ong CS; Gunawardana D; Blum R; Pearson J; Lodding J; Pietersz G; Broadbent R; Tait B; McKenzie IF
    J Immunother; 2001; 24(2):172-83. PubMed ID: 11265775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
    Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
    Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.
    Ioannides CG; Fisk B; Jerome KR; Irimura T; Wharton JT; Finn OJ
    J Immunol; 1993 Oct; 151(7):3693-703. PubMed ID: 7690810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
    Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
    Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
    Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
    J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential order of T and B cell epitopes affects immunogenicity but not antibody recognition of the B cell epitope.
    Denton G; Hudecz F; Kajtár J; Murray A; Tendler SJ; Price MR
    Pept Res; 1994; 7(5):258-64. PubMed ID: 7531518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
    Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ
    Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
    Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
    Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second generation anti-MUC1 peptide monoclonal antibodies.
    Xing PX; Prenzoska J; Quelch K; McKenzie IF
    Cancer Res; 1992 Apr; 52(8):2310-7. PubMed ID: 1373108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA.
    Jerome KR; Bu D; Finn OJ
    Cancer Res; 1992 Nov; 52(21):5985-90. PubMed ID: 1382849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neem leaf preparation enhances Th1 type immune response and anti-tumor immunity against breast tumor associated antigen.
    Mandal-Ghosh I; Chattopadhyay U; Baral R
    Cancer Immun; 2007 Mar; 7():8. PubMed ID: 17394284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.